Related references
Note: Only part of the references are listed.Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes
Christian Pecquet et al.
BLOOD (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Efficacious Intermittent Dosing of a Novel JAK2 Inhibitor in Mouse Models of Polycythemia Vera
Manfred Kraus et al.
PLOS ONE (2012)
New mutations and pathogenesis of myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2011)
Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets
Ana C. Glembotsky et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
ERK and cell death: Mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence
Sebastien Cagnol et al.
FEBS JOURNAL (2010)
Mouse Monoclonal Antibodies Against Human c-Mpl and Characterization for Flow Cytometry Applications
Christina Abbott et al.
HYBRIDOMA (2010)
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
A. Tefferi
LEUKEMIA (2010)
A Senescence-Like Cell-Cycle Arrest Occurs During Megakaryocytic Maturation: Implications for Physiological and Pathological Megakaryocytic Proliferation
Rodolphe Besancenot et al.
PLOS BIOLOGY (2010)
Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis
Brian J. Lannutti et al.
BLOOD (2009)
Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mp1 in platelets and terminally differentiated megakaryocytes
Ralph Tiedt et al.
BLOOD (2009)
Ras/MAPK signaling from endomembranes
Nicole Fehrenbacher et al.
MOLECULAR ONCOLOGY (2009)
Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics
Ayalew Tefferi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
From hematopoietic stem cells to platelets
Y. Chang et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Differential regulation and properties of MAPKs
M. Raman et al.
ONCOGENE (2007)
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Ross L. Levine et al.
NATURE REVIEWS CANCER (2007)
Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression
Alison R. Moliterno et al.
BLOOD (2006)
The molecular mechanisms that control thrombopoiesis
K Kaushansky
JOURNAL OF CLINICAL INVESTIGATION (2005)
Janus kinases affect thrombopoietin receptor cell surface localization and stability
Y Royer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity
M Ebisuya et al.
JOURNAL OF CELL SCIENCE (2005)
A novel strategy for generating platelet-like fragments from megakaryocytic cell lines and human progenitor cells
MJ Gandhi et al.
BLOOD CELLS MOLECULES AND DISEASES (2005)
Thrombopoietin-mediated sustained activation of extracellular signal-regulated kinase in UT7-Mpl cells requires both Ras-Raf-1-and Rap1-B-Raf-dependent pathways
J Garcia et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Share Paper
